• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

P2-33-4 * lung cancer chemotherapy in patients undergoing daialysis
Conclusion: Chemotherapy for lung cancer patients undergoing dialysis were associated with severe hematological toxicity.It is urgent task to establish optimal cancer chemotherapy and management of adverse events.
Source: Annals of Oncology - October 19, 2014 Category: Cancer & Oncology Authors: Sato, K., Kuriyama, H., Sakamoto, H., Ebe, Y., Koike, T. Tags: Poster Session (Poster presentations categorized by each organ) Source Type: research

P2-33-4 * lung cancer chemotherapy in patients undergoing daialysis
Conclusion: Chemotherapy for lung cancer patients undergoing dialysis were associated with severe hematological toxicity.It is urgent task to establish optimal cancer chemotherapy and management of adverse events.
Source: Annals of Oncology - October 19, 2014 Category: Cancer & Oncology Authors: Sato, K., Kuriyama, H., Sakamoto, H., Ebe, Y., Koike, T. Tags: Poster Session (Poster presentations categorized by each organ) Source Type: research

Subarachnoid Hemorrhage as the Initial Neurologic Manifestation in Thrombotic Thrombocytopenic Purpura (P6.014)
Conclusion: Upon review of the literature, ischemic infarction and intracerebral hemorrhage are uncommon complications of TTP. Our case demonstrates a unique case of subarachnoid hemorrhage as the initial neurological manifestation of TTP.Disclosure: Dr. Wei has nothing to disclose. Dr. Ramesh has nothing to disclose. Dr. Farmakidis has nothing to disclose. Dr. Nalleballe has nothing to disclose. Dr. JADEJA has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Wei, J., Ramesh, A., Farmakidis, C., Nalleballe, K., Jadeja, N. Tags: Cerebrovascular Disease and Interventional Neurology II ePosters Source Type: research

Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program Original Articles
Conclusions— In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Barnes, G. D., Stanislawski, M. A., Liu, W., Baron, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., Bradley, S. M. Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research

Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)
AbstractHemolytic uremic syndrome is commonly caused by Shiga toxin-producingEscherichia coli (STEC). Up to 15% of individuals with STEC-associated hemorrhagic diarrhea develop hemolytic uremic syndrome (STEC HUS). Hemolytic uremic syndrome (HUS) is a disorder comprising of thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The kidney is the most commonly affected organ and approximately half of the affected patients require dialysis. Other organ systems can also be affected including the central nervous system and the gastrointestinal, cardiac, and musculoskeletal systems. Neurological complicat...
Source: Pediatric Nephrology - October 29, 2019 Category: Urology & Nephrology Source Type: research